Score Overview
Explore the 2021 public Archive ranking →
Where ANI Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ANIP
2005: 87.8% · 2021: 59.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 74.83 | — |
1 Year2025-09-26 | $ 93.05 | -19.58% |
5 Years2021-09-28 | $ 32.80 | 128.14% |
10 Years2016-09-28 | $ 67.66 | 10.60% |
20 Years2006-09-28 | $ 57.60 | 29.91% |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 |
|---|---|---|---|---|---|
| Price | $ 74.83 | $ 93.05 | $ 32.80 | $ 67.66 | $ 57.60 |
| Return | — | -19.58% | 128.14% | 10.60% | 29.91% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 978M | $ 105M | $ 375M |
| 2025 | $ 883M | $ 78M | $ 285M |
| 2024 | $ 614M | -$ 18M | $ 151M |
| 2023 | $ 486M | $ 18M | $ 221M |
| 2022 | $ 316M | -$ 47M | $ 48M |
| 2021 | $ 216M | -$ 42M | $ 100M |
| 2020 | $ 208M | -$ 22M | $ 7M |
| 2019 | $ 206M | $ 6M | $ 62M |
| 2018 | $ 201M | $ 15M | $ 43M |
| 2017 | $ 176M | -$ 1M | $ 31M |
| 2016 | $ 128M | $ 3M | $ 27M |
| 2015 | $ 76M | $ 15M | $ 154M |
| 2014 | $ 55M | $ 28M | $ 169M |
| 2013 | $ 30M | $ 301K | $ 11M |
| 2012 | $ 2M | -$ 27M | $ 34M |
| 2011 | $ 435.16K | -$ 51M | $ 57M |
| 2010 | $ 2M | -$ 46M | $ 38M |
| 2009 | $ 1M | -$ 47M | $ 29M |
| 2008 | $ 3M | -$ 17M | $ 14M |
| 2007 | $ 493.05K | -$ 7M | $ 30M |
| 2006 | $ 14M | $ 2M | $ 11M |
| 2005 | $ 258.35K | -$ 9M | $ 9M |
| 2004 | $ 77.89K | -$ 12M | $ 17M |
| 2003 | $ 65.49K | -$ 5M | $ 9M |
| 2002 | $ 2M | -$ 3M | $ 4M |
| 2001 | $ 1M | -$ 2M | $ 4M |
| IPO2000 | -$ 3M | $ 2M |
ANI Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 208M to $ 883M and net income went from -$ 22M to $ 78M. Revenue increased in every one of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 76M to $ 883M and net income grew from $ 15M to $ 78M. Revenue increased in every one of those 10 years; net income in 4.
ANI Pharmaceuticals Inc currently holds a 20-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.
Membership
Continue ANIP’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
